A phase II study of the effectiveness of docetaxel (Taxotere) in women with advanced breast cancer previously treated with polychemotherapy

Abstract

Docetaxel is an active second-line drug in advanced breast cancer. The time of relapse after cessation of anthracycline treatment may be a significant prognostic factor.

Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure

“…Subsequent therapy in case of treatment failure is, therefore, a problem. Single-agent docetaxel has been proposed as an alternative treatment for patients previously treated with anthracyclinebased therapy; the efficacy of this drug has been demonstrated in pretreated patients with MBC (Ravdin et al, 1995;Valero et al, 1995;Nabholtz and Crown, 1998;Alexopoulos et al, 1999;Brodowicz et al, 2000).…”

“…In patients with anthracycline-resistant MBC, docetaxel (100 mg m 72 ), infused over 1 h every 3 weeks, induces ORRs ranging from 30 to 69% (Ravdin et al, 1995;Valero et al, 1995;Nabholtz and Crown, 1998;Alexopoulos et al, 1999;Brodowicz et al, 2000).…”

“…Subsequent therapy in case of treatment failure is, therefore, a problem. Single-agent docetaxel has been proposed as an alternative treatment for patients previously treated with anthracyclinebased therapy; the efficacy of this drug has been demonstrated in pretreated patients with MBC (Ravdin et al, 1995;Valero et al, 1995;Nabholtz and Crown, 1998;Alexopoulos et al, 1999;Brodowicz et al, 2000).In patients with anthracycline-resistant MBC, docetaxel (100 mg m 72 ), infused over 1 h every 3 weeks, induces ORRs ranging from 30 to 69% (Ravdin et al, 1995;Valero et al, 1995;Nabholtz and Crown, 1998;Alexopoulos et al, 1999;Brodowicz et al, 2000).Single-agent vinorelbine, in second-line or salvage chemotherapy for MBC, has a reported response rate of approximately 16% (Degardin et al, 1994;Gasparini et al, 1994), and the effectiveness of continuous infusion 5-FU in adenocarcinomas is well established (Caballero et al, 1985). A combination of vinorelbine plus 5-FU (FUN) has been administered to patients who have failed anthracycline therapy.…”

A phase I clinical and pharmacokinetic study of tipifarnib in combination with docetaxel in patients with advanced solid malignancies

“…The dose-limiting effects were largely confined to myelosuppression, and in particular, febrile neutropenia. Febrile neutropenia (approximately 25% [29][30][31][32][33][34] ) is often associated with docetaxel. Single-agent tipifarnib has previously been shown to have a low rate of febrile neutropenia (5%) in patients with refractory advanced colorectal cancer 35 .…”

Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer

“…Following first-line treatment with docetaxel, objective response rates of up to 68% have been reported (Chevallier et al, 1995;Dieras et al, 1996;Fumoleau et al, 1996a;Hudis et al, 1996). As second-line treatment for patients with disease resistant to anthracyclines, currently the most widely administered chemotherapeutic agents, docetaxel has achieved the highest activity to date (Ravdin et al, 1995;Valero et al, 1995;Alexopoulos et al, 1999;Nabholtz et al, 1999;Sjostrom et al, 1999).…”